Xantos Biomedicine AG and Cryptome Pharmaceuticals Ltd collaborate to validate cancer lead

21-Jun-2005 - Australia

Xantos Biomedicine AG announced that it has signed a collaboration agreement with Cryptome Pharmaceuticals Ltd, Melbourne, Australia. Xantos has used XantoScreen(TM) technology to discover novel proteins that mediate proliferation of vascular endothelial cells, which potentially play a role in the Formation of new blood vessels (angiogenesis) of tumours. Newly identified secreted proteins out of this screen have provided targets for inhibitory approaches aimed at depriving tumour cells from nutrients and oxygen. Simultaneously, such proteins may also serve as leads for the promotion of the growth of new blood vessels.

Cryptome has developed the unique Cryptomics(TM) drug discovery platform that rapidly identifies bioactive fragments whose function is locked within larger protein molecules. The company calls these fragments crypteins, and Cryptomics(TM) provides a high throughput means of finding them. Crypteins have multiple advantages over small molecules and antibodies as therapeutic agents and Cryptome is building a pipeline of drug candidates based on its technology. Cryptome will use Cryptomics(TM) to validate one of Xantos' valuable angiogenic therapeutic leads. The financial terms of the agreement are not disclosed but involve cash and milestone payments to CRP. Intellectual property rights for new therapeutic candidates will be assigned to Xantos.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances